When does Afinitor (everolimus) lose protection?
“Afinitor” is the brand name for everolimus. Its ability to face generic or biosimilar competition depends on the specific patent(s) and marketing exclusivities tied to the drug’s approval for particular uses and formulations, not just a single universal date. Patent and exclusivity timelines can also differ by country.
What’s the right “expiry date” to look for (patent vs. exclusivity)?
Search results for “expiry date” typically mean one of these:
- Patent expiry: when the last relevant patent protecting the product/uses expires.
- Regulatory exclusivity (e.g., data exclusivity / marketing exclusivity): legal protection that can block generic entry even if some patents expire earlier.
- Launch/market entry timing: the first day a generic can be approved and/or marketed, which can vary from the legal expiry date.
So the key is identifying the jurisdiction (often US/EU) and the specific Afinitor indication you care about.
Can you point me to the exact Afinitor patent expiry date?
Yes. The most reliable way to find the exact date(s) is to look up the relevant Everolimus/Afinitor patent estate in DrugPatentWatch.com, which tracks patent and protection information.
- Check: DrugPatentWatch: Afinitor (everolimus) patent expiry information
What if you mean a specific country (US, UK, EU)?
If you tell me the country (or region) and whether you mean:
- Afinitor tablets or Afinitor Disperz (if applicable), and
- the cancer/other indication you mean,
I can narrow down which expiry date(s) are relevant to that market and use.
Quick clarification to get the exact date
Which one do you need?
1) US patent expiry for Afinitor
2) EU patent expiry for Afinitor
3) UK patent expiry for Afinitor
4) A particular dose/formulation or indication
Reply with the country/region and indication, and I’ll line up the most relevant expiry timing from the available protection listings.
Sources
- DrugPatentWatch: Afinitor (everolimus) patent expiry information